Company: NIVFW
Filing Date: 2025-10-10
Form Type: F-1/A
Source: 0001213900-25-098135
Chunk: 195

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-10
Form: F-1/A
Chunk 195
---
 revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services. |

The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services are inter dependant. All the contracts have commercial substance, and it is probable that
the Company will collect considerations from its customers for service component as settlement is predominantly required prior to performance
of the promised service.

The Company derives its revenues
from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization (“IVF”)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various
procedures and treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion
of the service.

Revenue from surrogacy and ancillary caring services

The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately % of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to the Company’s result of operations
can be found in Note 8 below.

Revenue from egg freezing and storage facility

The Company provides access
the facility to its